IDS to begin study of CT laser mammography system under conditional IDE.
This article was originally published in The Gray Sheet
Executive Summary
IMAGING DIAGNOSTIC SYSTEMS' PAINLESS MAMMOGRAM TRIALS SET TO COMMENCE Feb. 28 at the Strax Breast Cancer Institute in Fort Lauderdale, Florida, the company says. On Feb. 13, FDA granted IDS a conditional investigational device exemption that allows preliminary clinical trials to begin with 50 patients. The trials are designed to show that IDS' Computed Tomography Laser Mammography (CTLM) technology, performed on the firm's proprietary scanning table, is a safe and effective diagnostic tool for breast cancer.